Literature DB >> 16289931

Hyperthermia induced by 3,4-methylenedioxymethamphetamine in unrestrained rhesus monkeys.

Michael A Taffe1, Christopher C Lay, Stefani N Von Huben, Sophia A Davis, Rebecca D Crean, Simon N Katner.   

Abstract

BACKGROUND: Exposure to (+/-)3,4-methylenedioxymethamphetamine ((+/-)MDMA) results in lasting reductions of many markers for serotonin terminals in a range of species. In rodents, the severity of insult depends in large part on the generation of hyperthermia in the subject. (+/-)MDMA can produce either hyperthermia or hypothermia in rodents depending on the ambient temperature and these effects may be limited to the S(+) enantiomer. Limited prior evidence suggests (+/-)MDMA does not produce hyperthermia in chair-restrained monkeys [Bowyer, J.F., Young, J.F., Slikker, W., Itzak, Y., Mayorga, A.J., Newport, G.D., Ali, S.F., Frederick, D.L., Paule, M.G., 2003. Plasma levels of parent compound and metabolites after doses of either d-fenfluramine or d-3,4-methylenedioxymethamphetamine (MDMA) that produce long-term serotonergic alterations. Neurotoxicology 24, 379-390]. This study was therefore conducted to determine if racemic MDMA and its enantiomers induce hyperthermia and increase spontaneous locomotor activity in unrestrained rhesus monkeys.
METHODS: Body temperature and spontaneous home cage activity were monitored continuously in four monkeys via radiotelemetric devices. The subjects were challenged with 1.7 mg/kg, i.m., (+/-)MDMA, S(+)MDMA and R(-)MDMA in pseudorandomized order.
RESULTS: Maximum and average temperature in the 4h interval post-dosing was elevated 0.7-0.9 degrees C by (+/-)MDMA and each enantiomer. Reductions in locomotor activity following dosing did not reliably differ from vehicle effects.
CONCLUSIONS: MDMA produces an acute hyperthermia in unrestrained rhesus monkeys, much as it does with rats, mice, pigs, rabbits and humans. Hyperthermia occurs despite no increase in locomotor activity thus the effect does not depend on motor activation. Each enantiomer appears to be equivalently active thus primates may differ from rodents in thermoregulatory sensitivity to the R(-) enantiomer. Significant differences in outcome between this and a prior study in monkeys indicate a need for additional study of the thermoregulatory impact of MDMA in nonhuman primates.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16289931      PMCID: PMC1551973          DOI: 10.1016/j.drugalcdep.2005.09.013

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  50 in total

1.  Chemical analysis of ecstasy pills.

Authors:  M Baggott; B Heifets; R T Jones; J Mendelson; E Sferios; J Zehnder
Journal:  JAMA       Date:  2000-11-01       Impact factor: 56.272

2.  Differential muscarinic and NMDA contributions to visuo-spatial paired-associate learning in rhesus monkeys.

Authors:  Michael A Taffe; Michael R Weed; Tannia Gutierrez; Sophia A Davis; Lisa H Gold
Journal:  Psychopharmacology (Berl)       Date:  2002-01-22       Impact factor: 4.530

3.  Performance norms for a rhesus monkey neuropsychological testing battery: acquisition and long-term performance.

Authors:  M R Weed; M A Taffe; I Polis; A C Roberts; T W Robbins; G F Koob; F E Bloom; L H Gold
Journal:  Brain Res Cogn Brain Res       Date:  1999-10-25

4.  The pharmacology of the acute hyperthermic response that follows administration of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') to rats.

Authors:  Annis O Mechan; Blanca Esteban; Esther O'Shea; J Martin Elliott; M Isabel Colado; A Richard Green
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

5.  Ultradian and circadian body temperature and activity rhythms in chronic MPTP treated monkeys.

Authors:  H Almirall; V Bautista; A Sánchez-Bahillo; M Trinidad-Herrero
Journal:  Neurophysiol Clin       Date:  2001-06       Impact factor: 3.734

6.  Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.

Authors:  M E Liechti; M R Saur; A Gamma; D Hell; F X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2000-10       Impact factor: 7.853

7.  Effect of 3,4-methylenedioxymethamphetamine ("ecstasy") on body temperature and liver antioxidant status in mice: influence of ambient temperature.

Authors:  Márcia Carvalho; Félix Carvalho; Fernando Remião; Maria de Lourdes Pereira; Ricardo Pires-das-Neves; Maria de Lourdes Bastos
Journal:  Arch Toxicol       Date:  2002-03-01       Impact factor: 5.153

8.  Cutaneous vasoconstriction contributes to hyperthermia induced by 3,4-methylenedioxymethamphetamine (ecstasy) in conscious rabbits.

Authors:  N P Pedersen; W W Blessing
Journal:  J Neurosci       Date:  2001-11-01       Impact factor: 6.167

9.  Functional consequences of repeated (+/-)3,4-methylenedioxymethamphetamine (MDMA) treatment in rhesus monkeys.

Authors:  M A Taffe; M R Weed; S Davis; S Huitrón-Resendiz; R Schroeder; L H Parsons; S J Henriksen; L H Gold
Journal:  Neuropsychopharmacology       Date:  2001-03       Impact factor: 7.853

10.  Rewarding effects of the optical isomers of 3,4-methylenedioxy-methylamphetamine ('Ecstasy') and 3,4-methylenedioxy-ethylamphetamine ('Eve') measured by conditioned place preference in rats.

Authors:  Anja Meyer; Andreas Mayerhofer; Karl-Artur Kovar; Werner J Schmidt
Journal:  Neurosci Lett       Date:  2002-09-27       Impact factor: 3.046

View more
  24 in total

Review 1.  A developmental comparison of the neurobehavioral effects of ecstasy (MDMA).

Authors:  Brian J Piper
Journal:  Neurotoxicol Teratol       Date:  2006-10-20       Impact factor: 3.763

2.  Effects of (+/-)3,4-methylenedioxymethamphetamine, (+/-)3,4-methylenedioxyamphetamine and methamphetamine on temperature and activity in rhesus macaques.

Authors:  R D Crean; S A Davis; S N Von Huben; C C Lay; S N Katner; M A Taffe
Journal:  Neuroscience       Date:  2006-07-28       Impact factor: 3.590

Review 3.  The hidden side of drug action: brain temperature changes induced by neuroactive drugs.

Authors:  Eugene A Kiyatkin
Journal:  Psychopharmacology (Berl)       Date:  2012-12-29       Impact factor: 4.530

Review 4.  The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivatives.

Authors:  J R Docherty; A R Green
Journal:  Br J Pharmacol       Date:  2010-07       Impact factor: 8.739

5.  Impact of ambient temperature on hyperthermia induced by (+/-)3,4-methylenedioxymethamphetamine in rhesus macaques.

Authors:  Stefani N Von Huben; Christopher C Lay; Rebecca D Crean; Sophia A Davis; Simon N Katner; Michael A Taffe
Journal:  Neuropsychopharmacology       Date:  2006-04-12       Impact factor: 7.853

6.  MDMA, Methylone, and MDPV: Drug-Induced Brain Hyperthermia and Its Modulation by Activity State and Environment.

Authors:  Eugene A Kiyatkin; Suelynn E Ren
Journal:  Curr Top Behav Neurosci       Date:  2017

7.  A comparison of intraperitoneal and subcutaneous temperature in freely moving rhesus macaques.

Authors:  Michael A Taffe
Journal:  Physiol Behav       Date:  2011-04-05

8.  In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3,4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats.

Authors:  Shawn M Aarde; Kevin M Creehan; Sophia A Vandewater; Tobin J Dickerson; Michael A Taffe
Journal:  Psychopharmacology (Berl)       Date:  2015-05-01       Impact factor: 4.530

9.  Oral administration of (+/-)3,4-methylenedioxymethamphetamine and (+)methamphetamine alters temperature and activity in rhesus macaques.

Authors:  Rebecca D Crean; Sophia A Davis; Michael A Taffe
Journal:  Pharmacol Biochem Behav       Date:  2007-04-03       Impact factor: 3.533

10.  Synthetic studies and pharmacological evaluations on the MDMA ('Ecstasy') antagonist nantenine.

Authors:  Onica Legendre; Stevan Pecic; Sandeep Chaudhary; Sarah M Zimmerman; William E Fantegrossi; Wayne W Harding
Journal:  Bioorg Med Chem Lett       Date:  2009-11-20       Impact factor: 2.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.